Kubota M, Mikawa H, Momoi T, Hosoi S, Nakato H
Department of Pediatrics, School of Medicine, Kyoto University.
Jpn J Antibiot. 1993 Nov;46(11):1030-4.
To evaluate the efficacy, the safety and the usefulness of a novel and esterified cephem antibiotic for oral use, S-1108, in pediatric infections, a clinical trial was performed. The study subjects were 15 patients including 9 with acute pharyngitis, 1 with acute tonsillitis, 2 with acute bronchitis, 1 with chronic pyelonephritis, 1 with acute abscess of the skin and 1 with impetigo contagiosa. S-1108 was administered orally at a dose of 3.7 mg/kg to 12.5 mg/kg t.i.d. for 4 to 9 days. Clinical effects were excellent in 7 cases, good in 6, fair in 1 and poor in 1. The Overall efficacy rate was 86.7%. Bacteriologically, causative organisms were all eradicated in evaluable 4 cases. As to side effects, diarrhea was observed in 2 cases. No abnormal laboratory test values were obtained.
为评估新型口服酯化头孢菌素抗生素S - 1108在儿科感染中的疗效、安全性和实用性,进行了一项临床试验。研究对象为15例患者,其中包括9例急性咽炎、1例急性扁桃体炎、2例急性支气管炎、1例慢性肾盂肾炎、1例皮肤急性脓肿和1例脓疱疮患者。S - 1108以3.7mg/kg至12.5mg/kg的剂量口服,每日3次,持续4至9天。临床疗效为7例优,6例良,1例中,1例差。总有效率为86.7%。细菌学方面,在可评估的4例病例中,致病微生物均被根除。至于副作用,2例出现腹泻。未获得异常的实验室检查值。